Table 6. Association rules of medications or their combinations and consecutive polypharmacy.
| Antecedent (ATC-4) | Support (%) | Confidence (%) | Lift |
|---|---|---|---|
| Glucocorticoids (H02AB) + HMG-CoA reductase inhibitors (C10AA) | 5.02 | 20.60 | 2.71 |
| Angiotensin-II receptor blockers (ARBs), plain (C09CA) + HMG-CoA reductase inhibitors | 5.10 | 20.40 | 2.68 |
| Angiotensin-II receptor blockers (ARBs), plain (C09CA) + Platelet aggregation inhibitors excl. heparin (B01AC) | 5.07 | 20.20 | 2.65 |
| HMG-CoA reductase inhibitors (C10AA) + Platelet aggregation inhibitors excl. heparin (B01AC) | 5.61 | 17.88 | 2.35 |
| H2-receptor antagonists (A02BA) | 5.52 | 16.85 | 2.21 |
| Third-generation cephalosporins (J01DD) | 5.15 | 16.04 | 2.11 |
| Angiotensin-II receptor blockers (ARBs), plain (C09CA) | 5.80 | 15.99 | 2.10 |
| Anilides (N02BE) | 5.69 | 15.94 | 2.09 |
| Platelet aggregation inhibitors excl. heparin (B01AC) | 6.31 | 15.05 | 1.98 |
| Vitamin D and analogues (A11CC) | 5.37 | 15.00 | 1.97 |
| HMG-CoA reductase inhibitors (C10AA) | 6.36 | 14.89 | 1.95 |
| Acetic acid derivatives and related substances (M01AB) | 5.44 | 14.78 | 1.94 |
| Glucocorticoids (H02AB) | 6.06 | 12.12 | 1.59 |
ATC, Anatomical Therapeutic Chemical classification.